Lilly and QurCan enter genetic-medicine collaboration worth up to $237m per programme

Lilly and QurCan Therapeutics have entered a multi-programme collaboration to develop nucleic-acid medicines for central and peripheral nervous system diseases using QurCan's TERP delivery platform.

QurCan's polymer-lipid nanoparticle technology is designed to deliver genetic medicines beyond the liver and will be applied to selected CNS and PNS targets under the collaboration.

QurCan is eligible for up to $237 million per programme in development and commercial milestones, as well as royalties, giving the agreement potentially substantial value across multiple programmes.

Field	Content
Alert Type	Deal
Companies	Eli Lilly and Company; QurCan Therapeutics
Deal Type	Strategic research and licensing collaboration
Asset or Company	TERP polymer-lipid nanoparticle delivery platform
Therapy Area(s)	Neurology; central nervous system; peripheral nervous system
Technology or Modality	Nucleic-acid therapeutics; polymer-lipid nanoparticles; genetic medicine
Deal Value	Up to US$237 million per programme in milestone payments, plus royalties
Geography	Global
What Happened	Lilly and QurCan Therapeutics entered a multi-programme collaboration to develop CNS and PNS genetic medicines using QurCan's TERP delivery technology.
Why It Matters	Efficient delivery remains a major challenge for genetic medicines outside the liver, and the collaboration gives Lilly access to a platform designed for broader tissue targeting.
Supporting Context	QurCan's TERP technology uses polymer-lipid nanoparticles designed to deliver nucleic-acid therapeutics to tissues including the central and peripheral nervous systems.
Strategic Rationale	Lilly gains access to a specialised delivery platform while QurCan receives development funding and potential milestone and royalty economics across multiple programmes.
Potential Impact	Successful programmes could expand the range of neurological diseases addressable with nucleic-acid medicines.
Key Takeaway	Lilly is partnering with QurCan on multiple genetic-medicine programmes, with potential payments of up to US$237 million per programme.
What to Watch	Selection of programme targets, preclinical development and evidence that TERP can achieve effective delivery in CNS and PNS tissues.
Primary Source	QurCan Therapeutics
Relevant Date	15 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com